title: Coated-platelets in ischemic stroke: differences between lacunar and cortical stroke.
abstract: BACKGROUND
  Coated-platelets are a subset of platelets with procoagulant potential observed upon dual agonist stimulation with collagen and thrombin.
  
  
  OBJECTIVE
  The goal was to investigate if coated-platelet production differs between patients with lacunar ischemic stroke and non-lacunar (cortical) ischemic stroke as compared with controls.
  
  
  METHODS
  Blood samples from 60 patients with ischemic stroke (20 lacunar and 40 cortical) and 70 controls were analyzed for coated-platelet production.
  
  
  RESULTS
  Coated-platelet production was significantly lower in patients with lacunar stroke (21.8 +/- 11.4%, mean +/- 1 SD) as compared with either controls (31.6 +/- 13.2%, P = 0.008) or patients with cortical stroke (39.4 +/- 12.7%, P < 0.001). The increase in coated-platelets for patients with cortical stroke as compared with controls was also significant (P = 0.008).
  
  
  CONCLUSIONS
  Our results indicate a marked difference in coated-platelet synthesis in lacunar vs. non-lacunar stroke, thereby providing additional support for the existence of distinct pathological processes underlying these two subtypes of ischemic stroke. Further investigation of the role of coated-platelets in stroke, taking into account these preliminary findings, is warranted.
authors.affiliation: VA Medical Center, Oklahoma City, OK, USA. calin-prodan@ouhsc.edu
authors.forename: C I
authors.initials: CI
authors.lastname: Prodan
authors.forename: P M
authors.initials: PM
authors.lastname: Joseph
authors.forename: A S
authors.initials: AS
authors.lastname: Vincent
authors.forename: G L
authors.initials: GL
authors.lastname: Dale
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001779:Blood Coagulation Factors / Q000032:analysis*; D001792:Blood Platelets / Q000737:chemistry* / Q000145:classification / Q000187:drug effects; D020520:Brain Infarction / Q000097:blood* / Q000453:epidemiology; D002545:Brain Ischemia / Q000097:blood* / Q000453:epidemiology; D003094:Collagen / Q000494:pharmacology; D015897:Comorbidity; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010976:Platelet Count; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D012907:Smoking / Q000453:epidemiology; D013917:Thrombin / Q000494:pharmacology
chemical_list: D001779:Blood Coagulation Factors; D003094:Collagen; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors; D013917:Thrombin; C049426:platelet procoagulant factor